1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Benzodiazepine APIs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Benzodiazepine APIs Market Analysis and Forecast, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Benzodiazepine Application Overview
5.2. Regulatory Scenario for Benzodiazepines in China and U.S.
5.3. Top 3 Markets for Clonazepam in Europe
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term impact)
6. Global Benzodiazepine APIs Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017 – 2031
6.3.1. Alprazolam
6.3.2. Bromazepam
6.3.3. Chlordiazepoxide
6.3.4. Clobazam
6.3.5. Clonazepam
6.3.6. Clorazepate
6.3.7. Diazepam
6.3.8. Lorazepam
6.3.9. Midazolam
6.3.10. Nitrazepam
6.3.11. Oxazepam
6.3.12. Temazepam
6.3.13. Others
6.4. Market Attractiveness, by Product
7. Global Benzodiazepine APIs Market Analysis and Forecast, by Time of Action
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Time of Action, 2017 – 2031
7.3.1. Short Acting
7.3.2. Intermediate
7.3.3. Long Acting
7.4. Market Attractiveness, by Time of Action
8. Global Benzodiazepine APIs Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017 – 2031
8.3.1. Pharmaceutical & Biotechnology Industries
8.3.2. CMOs
8.3.3. Others (Research Institutes, etc.)
8.4. Market Attractiveness, by End-user
9. Global Benzodiazepine APIs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America Benzodiazepine APIs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017 – 2031
10.2.1. Alprazolam
10.2.2. Bromazepam
10.2.3. Chlordiazepoxide
10.2.4. Clobazam
10.2.5. Clonazepam
10.2.6. Clorazepate
10.2.7. Diazepam
10.2.8. Lorazepam
10.2.9. Midazolam
10.2.10. Nitrazepam
10.2.11. Oxazepam
10.2.12. Temazepam
10.2.13. Others
10.3. Market Value Forecast, by Time of Action, 2017 – 2031
10.3.1. Short Acting
10.3.2. Intermediate
10.3.3. Long Acting
10.4. Market Value Forecast, by End-user, 2017 – 2031
10.4.1. Pharmaceutical & Biotechnology Industries
10.4.2. CMOs
10.4.3. Others (Research Institutes, etc.)
10.5. Market Value Forecast, by Country, 2017 – 2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Time of Action
10.6.3. By End-user
10.6.4. By Country
11. Europe Benzodiazepine APIs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017 – 2031
11.2.1. Alprazolam
11.2.2. Bromazepam
11.2.3. Chlordiazepoxide
11.2.4. Clobazam
11.2.5. Clonazepam
11.2.6. Clorazepate
11.2.7. Diazepam
11.2.8. Lorazepam
11.2.9. Midazolam
11.2.10. Nitrazepam
11.2.11. Oxazepam
11.2.12. Temazepam
11.2.13. Others
11.3. Market Value Forecast, by Time of Action, 2017 – 2031
11.3.1. Short Acting
11.3.2. Intermediate
11.3.3. Long Acting
11.4. Market Value Forecast, by End-user, 2017 – 2031
11.4.1. Pharmaceutical & Biotechnology Industries
11.4.2. CMOs
11.4.3. Others (Research Institutes, etc.)
11.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Time of Action
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Benzodiazepine APIs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017 – 2031
12.2.1. Alprazolam
12.2.2. Bromazepam
12.2.3. Chlordiazepoxide
12.2.4. Clobazam
12.2.5. Clonazepam
12.2.6. Clorazepate
12.2.7. Diazepam
12.2.8. Lorazepam
12.2.9. Midazolam
12.2.10. Nitrazepam
12.2.11. Oxazepam
12.2.12. Temazepam
12.2.13. Others
12.3. Market Value Forecast, by Time of Action, 2017 – 2031
12.3.1. Short Acting
12.3.2. Intermediate
12.3.3. Long Acting
12.4. Market Value Forecast, by End-user, 2017 – 2031
12.4.1. Pharmaceutical & Biotechnology Industries
12.4.2. CMOs
12.4.3. Others (Research Institutes, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of APAC
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Time of Action
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Benzodiazepine APIs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017 – 2031
13.2.1. Alprazolam
13.2.2. Bromazepam
13.2.3. Chlordiazepoxide
13.2.4. Clobazam
13.2.5. Clonazepam
13.2.6. Clorazepate
13.2.7. Diazepam
13.2.8. Lorazepam
13.2.9. Midazolam
13.2.10. Nitrazepam
13.2.11. Oxazepam
13.2.12. Temazepam
13.2.13. Others
13.3. Market Value Forecast, by Time of Action, 2017 – 2031
13.3.1. Short Acting
13.3.2. Intermediate
13.3.3. Long Acting
13.4. Market Value Forecast, by End-user, 2017 – 2031
13.4.1. Pharmaceutical & Biotechnology Industries
13.4.2. CMOs
13.4.3. Others (Research Institutes, etc.)
13.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Time of Action
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Benzodiazepine APIs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017 – 2031
14.2.1. Alprazolam
14.2.2. Bromazepam
14.2.3. Chlordiazepoxide
14.2.4. Clobazam
14.2.5. Clonazepam
14.2.6. Clorazepate
14.2.7. Diazepam
14.2.8. Lorazepam
14.2.9. Midazolam
14.2.10. Nitrazepam
14.2.11. Oxazepam
14.2.12. Temazepam
14.2.13. Others
14.3. Market Value Forecast, by Time of Action, 2017 – 2031
14.3.1. Short Acting
14.3.2. Intermediate
14.3.3. Long Acting
14.4. Market Value Forecast, by End-user, 2017 – 2031
14.4.1. Pharmaceutical & Biotechnology Industries
14.4.2. CMOs
14.4.3. Others (Research Institutes, etc.)
14.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Time of Action
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Sun Pharmaceutical Industries Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Merck KGaA
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. LGC GmbH (LGC Science Group Holdings Limited)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Nortec Química S.A.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Centaur Pharmaceuticals
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Eisai Co., Ltd
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Global Calcium PVT LTD
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Delphis Pharma
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Mylan N.V. (Viatris Inc.)
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Taj Pharmaceuticals Ltd.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
